Reset filter
Palavras-chave
Onkologie, medizinische ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

483 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 13 Elementos de dados, 1 Idioma
Grupo de itens: Biopsy
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: End of Treatment. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Eligibility Lymphoma NCT02056548

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 12 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Eligibility Carcinoma NCT01061645

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 15 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Study of MOC31-PE in Antigen Positive Carcinomas; ODM derived from: https://clinicaltrials.gov/show/NCT01061645

Patient Admision Pediatric Hematology and Oncology UK Muenster

- 20/09/2021 - 1 Formulário, 18 Grupos de itens, 195 Elementos de dados, 2 Idiomas
Grupos de itens: Patient, Father, Mother, Living arrangement, Sibling, Medical history, Nursing support, Support device, Personal aids, School, Kindergarten, workshop, Therapies in school, kindergarten, workshop, Medication, Medication history, Therapy, Nutrition, Continence, Catheters and drainages, Other
Freigabe zur Verarbeitung durch Frau Prof. Rössig, Quellenangabe: "Pädiatrische Hämatologie und Onkologie, UKM" Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Münster Released for adaption by Frau Prof. Rössig Source:Pediatric Hematology und Oncology, University hospital Münster

Eligibility Renal Cell Carcinoma NCT00610389

- 20/09/2021 - 1 Formulário, 2 Grupos de itens, 11 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Thrombosis Registry Oncology Thromboses UK Essen - Thrombosis

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 23 Elementos de dados, 1 Idioma
Grupo de itens: Thrombosis
Study part: Thrombosis Registry for oncologic patients with thromboses. The aim of the study was to determine the incidence of thrombosis in oncology patients. A register study of University Clinic Essen (UK Essen), permission granted by Claudia Ose from the Center for Clinical Studies Essen (Zentrums für Klinische Studien Essen, ZKSE).

"Mamma carcinoma"- Additions to the ADT-base record - Organ specific data set for mamma carcinoma: January 2015

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 2 Idiomas
Grupo de itens: Data set mamma carcinoma
The uniform oncological basic data set of ADT and GEKID was adopted in March 2008 and updated in February, 2014. It applies to all types of cancer and is continuously supplemented by tumor-specific modules. By harmonizing Oncology base record, an instrument has been created which provides a harmonized oncological standard , prevents multiple documentaries and allows comparable acquisition and evaluation of cancer treatments in all clinical structures and federal states . Source: http://www.tumorzentren.de/onkol-basisdatensatz.html

Liver tumor tumor board Oncology Form University Hospital Cologne

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 41 Elementos de dados, 1 Idioma
Grupo de itens: Liver tumor tumor board request
Liver tumor tumor board request form at the endocrinology polyclinic department University Hospital Cologne. Asking questions regarding basic patient information, tumor board organisation, diagnosis and comorbidity, pathology and tumor staging as well as diagnostic imaging. ODM derived from routine documentation of University Hospital Cologne.

Patient status (DKKR)

- 20/09/2021 - 1 Formulário, 1 Grupo de itens, 27 Elementos de dados, 2 Idiomas
Grupo de itens: Administrative Documentation
German Pediatric Oncology Registry http://www.kinderkrebsregister.de

Eligibility Stage I/II Extranodal NK/T-cell Lymphoma NCT02276248

- 17/09/2021 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma
Grupos de itens: Inclusion Criteria, Exclusion Criteria
Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02276248

Topotecan (HycamtinTM) with Carboplatin as First-Line Chemotherapy in Patients with Ovarian Cancer; 104864/612 - Baseline

- 17/09/2021 - 1 Formulário, 19 Grupos de itens, 80 Elementos de dados, 1 Idioma
Grupos de itens: Administrative documentation, Assessment Date, Demography, Menopausal Status, Medical History, Symptoms, Study Start Date, Concomitant Agent, ECOG performance status, Personal history of malignant neoplasm, unspecified, Ovarian Carcinoma, Histology, Ovarian Carcinoma, Operative Surgical Procedures, Tumor stage, Tumor Markers, Physical Examination, Lower abdomen, X-Ray Computed Tomography, Plain x-ray, Electrocardiography, Questionnaires, Quality of life, Receptor
Study ID: 104864/612 Clinical Study ID: 104864/612 Study Title: A Prospective, Open Label Phase II Study to Evaluate the Efficacy and Safety of Topotecan (HycamtinTM) in Combination with Carboplatin as First-line Chemotherapy in Patients with Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: HycamtinTM Study Indication: Ovarian Cancer

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial